Pharma & Immunology
Regeneron Pharmaceuticals beats estimates on strong drug demand
By Intent.Health Team • April 29, 2026
What’s happening
Regeneron reported better-than-expected earnings, supported by strong demand for: Dupixent (immunology) and Libtayo (oncology).
What’s changing / Business impact
-
Continued strength in: immunology and oncology markets.
-
Revenue stability despite competition.
Why this matters
Certain therapeutic areas remain consistently strong.
This shows:
-
Chronic + specialty conditions drive reliable demand.
-
Established therapies continue generating long-term revenue.
-
Pharma growth is concentrated in high-value disease areas.